Subpatent infection with nucleoside transporter 1-deficient Plasmodium blood stage parasites confers sterile protection against lethal malaria in mice

Cellular Microbiology

Volumn 12, Issue 7, 2010, Pages 930-938

  Aly, Ahmed S I ^a   Downie, Megan J ^b   Mamoun, Choukri Ben ^b   Kappe, Stefan H I ^a,c  

^a SEATTLE BIOMEDICAL RESEARCH INSTITUTE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; MALARIA VACCINE; PLASMODIUM FALCIPARUM NUCLEOSIDE TRANSPORTER1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOODSTREAM INFECTION; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; GENETIC MANIPULATION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; MALARIA; MICROBIAL ATTENUATION; MOUSE; NONHUMAN; PARASITEMIA; PLASMODIUM BERGHEI; PLASMODIUM FALCIPARUM; PLASMODIUM MALARIAE INFECTION; PLASMODIUM YOELII; PRIORITY JOURNAL; SPOROZOITE; VACCINATION;

ANIMALS; FEMALE; MALARIA; MALARIA VACCINES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NUCLEOSIDE TRANSPORT PROTEINS; PLASMODIUM; PLASMODIUM YOELII; PROTOZOAN PROTEINS;

MUS; PLASMODIUM BERGHEI; PLASMODIUM FALCIPARUM; PLASMODIUM YOELII; RODENTIA;

EID: 77953543454     PISSN: 14625814     EISSN: 14625822     Source Type: Journal    
DOI: 10.1111/j.1462-5822.2010.01441.x     Document Type: Article

References (30)

1. Aly AS, Mikolajczak SA, Rivera HS, Camargo N, Jacobs-Lorena V, Labaied M. Targeted deletion of SAP1 abolishes the expression of infectivity factors necessary for successful malaria parasite liver infection. Mol Microbiol 2008, 69:152-163.
2. Carter NS, Ben Mamoun C, Liu W, Silva EO, Landfear SM, Goldberg DE, Ullman B. Isolation and functional characterization of the PfNT1 nucleoside transporter gene from Plasmodium falciparum. J Biol Chem 2000, 275:10683-10691.
3. Clyde DF, Most H, McCarthy VC, Vanderberg JP. Immunization of man against sporozite-induced falciparum malaria. Am J Med Sci 1973, 266:169-177.
4. Collins WE, Jeffery GM. A retrospective examination of sporozoite- and trophozoite-induced infections with Plasmodium falciparum in patients previously infected with heterologous species of Plasmodium: effect on development of parasitologic and clinical immunity. Am J Trop Med Hyg 1999a, 61:36-43.
5. Collins WE, Jeffery GM. A retrospective examination of sporozoite- and trophozoite-induced infections with Plasmodium falciparum: development of parasitologic and clinical immunity during primary infection. Am J Trop Med Hyg 1999b, 61:4-19.
6. Downie MJ, Kirk K, Mamoun CB. Purine salvage pathways in the intraerythrocytic malaria parasite Plasmodium falciparum. Eukaryot Cell 2008, 7:1231-1237.
7. El Bissati K, Zufferey R, Witola WH, Carter NS, Ullman B, Ben Mamoun C. The plasma membrane permease PfNT1 is essential for purine salvage in the human malaria parasite Plasmodium falciparum. Proc Natl Acad Sci USA 2006, 103:9286-9291.
8. El Bissati K, Downie MJ, Kim SK, Horowitz M, Carter N, Ullman B, Ben Mamoun C. Genetic evidence for the essential role of PfNT1 in the transport and utilization of xanthine, guanine, guanosine and adenine by Plasmodium falciparum. Mol Biochem Parasitol 2008, 161:130-139.
9. Elliott SR, Kuns RD, Good MF. Heterologous immunity in the absence of variant-specific antibodies after exposure to subpatent infection with blood-stage malaria. Infect Immun 2005, 73:2478-2485.
10. Good MF. The hope but challenge for developing a vaccine that might control malaria. Eur J Immunol 2009, 39:939-943.
11. Greenwood BM, Bojang K, Whitty CJ, Targett GA. Malaria. Lancet 2005, 365:1487-1498.
12. Jones TR, Obaldia N, Gramzinski RA, Hoffman SL. Repeated infection of Aotus monkeys with Plasmodium falciparum induces protection against subsequent challenge with homologous and heterologous strains of parasite. Am J Trop Med Hyg 2000, 62:675-680.
13. Landau I, Chabaud AG. [Natural infection by 2 plasmodia of the rodent Thamnomys rutilans in the Central African Republic]. C R Hebd Seances Acad Sci 1965, 261:230-232.
14. McCarthy JS, Good MF. Whole parasite blood stage malaria vaccines: a convergence of evidence. Hum Vaccin 2010, 6:114-123.
15. Madrid DC, Ting LM, Waller KL, Schramm VL, Kim K. Plasmodium falciparum purine nucleoside phosphorylase is critical for viability of malaria parasites. J Biol Chem 2008, 283:35899-35907.
16. Moorthy VS, Diggs C, Ferro S, Good MF, Herrera S, Hill AV. Report of a consultation on the optimization of clinical challenge trials for evaluation of candidate blood stage malaria vaccines, 18-19 March 2009, Bethesda, MD, USA. Vaccine 2009, 27:5719-5725.
17. Nussenzweig RS, Vanderberg J, Most H, Orton C. Protective immunity produced by the injection of x-irradiated sporozoites of Plasmodium berghei. Nature 1967, 216:160-162.
18. Ogutu BR, Apollo OJ, McKinney D, Okoth W, Siangla J, Dubovsky F. Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya. PLoS One 2009, 4:e4708.
19. Parker MD, Hyde RJ, Yao SY, McRobert L, Cass CE, Young JD. Identification of a nucleoside/nucleobase transporter from Plasmodium falciparum, a novel target for anti-malarial chemotherapy. Biochem J 2000, 349:67-75.
20. Pombo DJ, Lawrence G, Hirunpetcharat C, Rzepczyk C, Bryden M, Cloonan N. Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum. Lancet 2002, 360:610-617.
21. Rager N, Mamoun CB, Carter NS, Goldberg DE, Ullman B. Localization of the Plasmodium falciparum PfNT1 nucleoside transporter to the parasite plasma membrane. J Biol Chem 2001, 276:41095-41099.
22. Sagara I, Dicko A, Ellis RD, Fay MP, Diawara SI, Assadou MH. A randomized controlled phase 2 trial of the blood stage AMA1-C1/Alhydrogel malaria vaccine in children in Mali. Vaccine 2009, 27:3090-3098.
23. Sinden RE, Dawes EJ, Alavi Y, Waldock J, Finney O, Mendoza J. Progression of Plasmodium berghei through Anopheles stephensi is density-dependent. PLoS Pathog 2007, 3:e195.
24. Snow RW, Guerra CA, Noor AM, Myint HY, Hay SI. The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature 2005, 434:214-217.
25. Ting LM, Gissot M, Coppi A, Sinnis P, Kim K. Attenuated Plasmodium yoelii lacking purine nucleoside phosphorylase confer protective immunity. Nat Med 2008, 14:954-958.
26. Weinbaum FI, Evans CB, Tigelaar RE. An in vitro assay for T cell immunity to malaria in mice. J Immunol 1976, 116:1280-1283.
27. Weiss WR, Good MF, Hollingdale MR, Miller LH, Berzofsky JA. Genetic control of immunity to Plasmodium yoelii sporozoites. J Immunol 1989, 143:4263-4266.
28. Wipasa J, Xu H, Liu X, Hirunpetcharat C, Stowers A, Good MF. Effect of Plasmodium yoelii exposure on vaccination with the 19-kilodalton carboxyl terminus of merozoite surface protein 1 and vice versa and implications for the application of a human malaria vaccine. Infect Immun 2009, 77:817-824.
29. Wykes MN, Good MF. What have we learnt from mouse models for the study of malaria? Eur J Immunol 2009, 39:2004-2007.
30. Yoeli M, Hargreaves B, Carter R, Walliker D. Sudden increase in virulence in a strain of Plasmodium berghei yoelii. Ann Trop Med Parasitol 1975, 69:173-178.